RZLT
Rezolute, Inc. Health Care Pharmaceutical Preparations Russell 3000
$3.95Close
$380.8MMarket cap
$1.40 – $10.9452-week range
Nov 5, 2026Next report
Highlights
Cautions
- Not in an uptrend 4 of 8 trend conditions
- Lagging the market RS 24 · weaker than 76% of stocks over 12 months
- Far from its high 64% below its 52-week high
- Results soon Nov 5, 2026, in 4 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
64%
1wk
up 2.5%
price change
1mo
down 4.6%
price change
12-month return
down 60%
market up 11% ·
its own down 69%
F-score
—
— Not assessed
Altman Z
—
Unknown
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
3.8×
price / book
Earnings yield
down 22.4%
EBIT / enterprise value
Cheaper than
—
of the market · not assessed
Revenue growth
—
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
down 59%
return on equity
Free cash margin
—
-$64.6M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
7.4%
$0.29 a day · 2×ATR $3.36
RS
24 / 99
vs the universe
Trend
4 / 8
trend template
Relative volume
0.5×
vs 50-day average
Up/down volume
0.90
50 sessions
Implied move
—
no option chain · report Nov 5, 2026
Contractions
2
35% → 31%
Pivot
$4.91
19.6% below
Volume dry-up
0.8×
10 vs 50 sessions
Trend template · 4 of 8
- Price above the 150 and 200-day averages: fails
- 150-day average above the 200-day: passes
- 200-day average rising for a month: passes
- 50-day average above the 150 and 200-day: passes
- Price above the 50-day average: fails
- At least 30% above the 52-week low: passes
- Within 25% of the 52-week high: fails
- RS rank 70 or higher: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 10.8% over the year, from 87m to 96m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Sep 24, 2026
Results reaction
Sep 24, 2026-3% vs market2 sessions after results
Financials
- Cash
- Long-term debt
| FY2021Jun 30, 2021 | FY2022Jun 30, 2022 | FY2023Jun 30, 2023 | FY2024Jun 30, 2024 | FY2025Jun 30, 2025 | FY2026Jun 30, 2026 | |
|---|---|---|---|---|---|---|
| Operating income | -$22.9M | -$41.8M | -$56.0M | -$70.4M | -$79.9M | -$83.0M |
| Net income | -$20.9M | -$41.1M | -$51.8M | -$68.5M | -$74.4M | -$77.6M |
| Earnings per share | -$2.72 | -$2.11 | -$1.01 | -$1.33 | -$0.98 | -$0.75 |
| Free cash flow | -$20.4M | -$39.6M | -$44.6M | -$57.4M | -$69.1M | -$64.6M |
| Cash | $41.0M | $150.4M | $16.0M | $70.4M | $94.1M | $10.6M |
| Long-term debt | $14.0M | — | — | — | — | — |
| Shareholders' equity | $26.1M | $149.5M | $116.2M | $121.0M | $162.1M | $100.7M |
| Shares outstanding | 8.35m | 33.58m | 36.83m | 53.25m | 87m | 96.41m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Sep 24, 2026 | Annual ↗ | Jun 30, 2026 | 86d |
| May 12, 2026 | Quarterly ↗ | Mar 31, 2026 | 42d |
| Feb 12, 2026 | Quarterly ↗ | Dec 31, 2025 | 43d |
| Nov 6, 2025 | Quarterly ↗ | Sep 30, 2025 | 37d |
| Sep 17, 2025 | Annual ↗ | Jun 30, 2025 | 79d |
| May 13, 2025 | Quarterly ↗ | Mar 31, 2025 | 43d |
| Feb 12, 2025 | Quarterly ↗ | Dec 31, 2024 | 43d |
| Nov 7, 2024 | Quarterly ↗ | Sep 30, 2024 | 38d |
| Sep 19, 2024 | Annual ↗ | Jun 30, 2024 | 81d |
| May 15, 2024 | Quarterly ↗ | Mar 31, 2024 | 45d |
| Feb 13, 2024 | Quarterly ↗ | Dec 31, 2023 | 44d |
| Nov 13, 2023 | Quarterly ↗ | Sep 30, 2023 | 44d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 29, 2026 | Regulation FD ↗ |
| Oct 14, 2026 | Regulation FD ↗ |
| Oct 5, 2026 | Regulation FD ↗ |
| Sep 24, 2026 | Results ↗ |
| Jun 2, 2026 | Regulation FD ↗ |
| May 12, 2026 | Results ↗ |
| May 4, 2026 | Regulation FD ↗ |
| Mar 24, 2026 | Regulation FD ↗ |
| Feb 12, 2026 | Results ↗ |
| Jan 7, 2026 | Regulation FD ↗ |
| Nov 21, 2025 | Shareholder vote ↗ |
| Nov 12, 2025 | Regulation FD ↗ |